This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (August 2024) |
Sunvozertinib (trade name 舒沃哲) is a pharmaceutical drug for the treatment of non-small-cell lung cancer (NSCLC).[1][2] It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.[1][3]
![]() | |
Clinical data | |
---|---|
Trade names | 舒沃哲 |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
Chemical and physical data | |
Formula | C29H35ClFN7O3 |
Molar mass | 584.09 g·mol−1 |
3D model (JSmol) | |
|
History
editSunvozertinib is being developed by Dizal Pharmaceutical.[4] In China, it was conditionally approved in 2023 for the treatment of NSCLC and full approval is contingent on results of phase 3 clinical trials.[5] In the United States, it has been designated by the Food and Drug Administration as a breakthrough therapy for patients with locally advanced or metastatic NSCLCs with an EGFR exon 20 insertion mutation.[6]
References
edit- ^ a b Wang, Mengzhao; Yang, James Chih-Hsin; Mitchell, Paul L.; Fang, Jian; Camidge, D. Ross; Nian, Weiqi; Chiu, Chao-Hua; Zhou, Jianying; Zhao, Yanqiu; Su, Wu-Chou; Yang, Tsung-Ying; Zhu, Viola W.; Millward, Michael; Fan, Yun; Huang, Wen-Tsung; Cheng, Ying; Jiang, Liyan; Brungs, Daniel; Bazhenova, Lyudmila; Lee, Chee Khoon; Gao, Bo; Xu, Yan; Hsu, Wei-Hsun; Zheng, Li; Jänne, Pasi A. (2022). "Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations". Cancer Discovery. 12 (7): 1676–1689. doi:10.1158/2159-8290.CD-21-1615. PMC 9262839. PMID 35404393.
- ^ Wang, Mengzhao; et al. (2024). "Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): Single-arm, open-label, multicentre, phase 2 trial". The Lancet Respiratory Medicine. 12 (3): 217–224. doi:10.1016/S2213-2600(23)00379-X. PMID 38101437.
- ^ Hidetoshi Hayashi (2024). "Sunvozertinib: the next candidate of TKI for NSCLC". The Lancet Respirator Medicine. 12 (3): 185–186. doi:10.1016/S2213-2600(23)00419-8. PMID 38101435.
- ^ "ASH: With high tumor response, AstraZeneca spinout Dizal explores FDA path and US partner for PTCL drug". Fierce Biotech. Dec 11, 2023.
- ^ Dhillon, Sohita (2023). "Sunvozertinib: First Approval". Drugs. 83 (17): 1629–1634. doi:10.1007/s40265-023-01959-5. PMID 37962831.
- ^ "FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC". targetedonc.com. April 9, 2024.